

ALG9 (Y-12): sc-109496

BACKGROUND

Glycosylation of asparagine residues is an essential protein modification reaction that occurs upon most proteins that enter the secretory pathway in eukaryotic cells. Asparagine-linked oligosaccharides are transferred onto polypeptides in the lumen of the rough endoplasmic reticulum. ALG9 (asparagine-linked glycosylation 9, α -1,2-mannosyltransferase homolog), also known as DIBD1, is a 611 amino acid multi-pass membrane protein that localizes to the endoplasmic reticulum. Ubiquitously expressed, with highest levels in heart, liver and pancreas, ALG9 catalyzes the transfer of mannose from Dol-P-Man to lipid-linked oligosaccharides. Defects in the gene encoding ALG9 may be caused by congenital disorder of glycosylation type 1L (CDG1L). CDGs are a family of severe inherited diseases, including psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders and immunodeficiency, caused by a defect in protein N-glycosylation and are characterized by under-glycosylated serum proteins. Four isoforms of ALG9 exist due to alternative splicing events.

REFERENCES

- de L Ufret, M. and Imperiali, B. 2000. Probing the extended binding determinants of oligosaccharyl transferase with synthetic inhibitors of asparagine-linked glycosylation. *Bioorg. Med. Chem. Lett.* 10: 281-284.
- Nagayama, Y., et al. 2000. Identification of the sites of asparagine-linked glycosylation on the human thyrotropin receptor and studies on their role in receptor function and expression. *J. Pharmacol. Exp. Ther.* 295: 404-409.
- Uchimura, S., et al. 2005. Effects of N-glycosylation and inositol on the ER stress response in yeast *Saccharomyces cerevisiae*. *Biosci. Biotechnol. Biochem.* 69: 1274-1280.
- Bickel, T., et al. 2005. Biosynthesis of lipid-linked oligosaccharides in *Saccharomyces cerevisiae*: Alg13p and Alg14p form a complex required for the formation of GlcNAc(2)-PP-dolichol. *J. Biol. Chem.* 280: 34500-34506.
- Gao, X.D., et al. 2005. ALG14 recruits ALG13 to the cytoplasmic face of the endoplasmic reticulum to form a novel bipartite UDP-N-acetylglucosamine transferase required for the second step of N-linked glycosylation. *J. Biol. Chem.* 280: 36254-36262.
- Averbeck, N., et al. 2007. Membrane topology of the ALG14 endoplasmic reticulum UDP-GlcNAc transferase subunit. *J. Biol. Chem.* 282: 29081-29088.
- Gao, X.D., et al. 2008. Interaction between the C termini of ALG13 and ALG14 mediates formation of the active UDP-N-acetylglucosamine transferase complex. *J. Biol. Chem.* 283: 32534-32541.
- Averbeck, N., et al. 2008. Alg13p, the catalytic subunit of the endoplasmic reticulum UDP-GlcNAc glycosyltransferase, is a target for proteasomal degradation. *Mol. Biol. Cell* 19: 2169-2178.
- Wang, X., et al. 2008. Solution structure of ALG13: the sugar donor subunit of a yeast N-acetylglucosamine transferase. *Structure* 16: 965-975.

CHROMOSOMAL LOCATION

Genetic locus: ALG9 (human) mapping to 11q23.1; Alg9 (mouse) mapping to 9 A5.3.

SOURCE

ALG9 (Y-12) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of ALG9 of human origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-109496 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

ALG9 (Y-12) is recommended for detection of ALG9 isoforms 1 and 3 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with ALG9 isoforms 2 or 4.

ALG9 (Y-12) is also recommended for detection of ALG9 isoforms 1 and 3 in additional species, including equine, canine, bovine, porcine and avian.

Suitable for use as control antibody for ALG9 siRNA (h): sc-96648, ALG9 siRNA (m): sc-141017, ALG9 shRNA Plasmid (h): sc-96648-SH, ALG9 shRNA Plasmid (m): sc-141017-SH, ALG9 shRNA (h) Lentiviral Particles: sc-96648-V and ALG9 shRNA (m) Lentiviral Particles: sc-141017-V.

Molecular Weight of ALG9: 70 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.